RxDoctor Payments Data

Jodi Conley, PA

Physician Assistant · Grayson, KYNPI 1891860599

Payments from drug & device makers

$6,241in general payments, 2019–2025

Across 373 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AbbVie$860
  • Lilly USA, LLC$665
  • Novo Nordisk$648
  • AstraZeneca$622
  • Grifols USA, LLC$246
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$6,229100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,241 in reported general payments places this provider in the 90th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$98,905
Medicare patients
243
Services billed
1,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate171$153,645
OzempicSemaglutide99$129,423
EliquisApixaban96$98,926
MounjaroTirzepatide70$98,583
AustedoDeutetrabenazine12$64,838
RybelsusSemaglutide37$56,503
XareltoRivaroxaban33$41,396
Tresiba Flextouch U-200Insulin Degludec19$38,659
LinzessLinaclotide39$37,314
MyrbetriqMirabegron33$30,695
FarxigaDapagliflozin Propanediol32$28,112
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$27,907
JardianceEmpagliflozin34$27,365
EntrestoSacubitril/Valsartan28$18,975
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog44$18,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$648$185,926136 claims
MerckJanuvia$170$153,645171 claims
PfizerEliquis$196$98,92696 claims
Lilly USA, LLCMounjaro$665$98,58370 claims
Teva Pharmaceuticals USA, Inc.Austedo$56$64,83812 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta$622$49,87579 claims
AbbVieLinzess, Ubrelvy$860$49,17951 claims
Boehringer IngelheimJardiance, Tradjenta$71$39,24445 claims
GSKTrelegy Ellipta, Breo Ellipta$1,113$37,40339 claims
NovartisEntresto$81$18,97528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Grayson

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →